Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

AbbVie expects Botox boom to power annual earnings

Stock MarketsJul 30, 2021 16:10
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder

By Manas Mishra and Amruta Khandekar

(Reuters) -Drugmaker AbbVie Inc (NYSE:ABBV) on Friday raised its 2021 profit forecast on expectations that a rapid uptick in demand for its Botox anti-wrinkle injection due to the easing of COVID-19 curbs would continue for the rest of the year.

Sales of the drug for cosmetic uses rose two-fold to $584 million in the second quarter, trouncing analysts' estimates of $483 million as vaccinations encouraged people to resume non-essential procedures after being holed up at home for months.

The company acquired the drug last year as part of its $63 billion purchase of Allergan (NYSE:AGN). Company executives said on an earnings call that sales of products gained through the deal were on track to outpace Allergan's historical performance.

Increased investment in Botox and other aesthetic products is helping boost demand, Chief Executive Officer Richard Gonzalez said.

"About two-thirds of the performance, I think, is fundamental demand and maybe one-third of it is pent-up demand," Gonzalez added.

The company forecast full-year adjusted earnings between $12.52 and $12.62 per share, compared with $12.37 to $12.57 per share previously. Analysts expected 2021 earnings per share of $12.61, according to Refinitiv IBES data.

AbbVie also reported a 4.8% rise in quarterly sales of its best-selling drug Humira to $5.07 billion, roughly in line with expectations.

But sales of the drug, which is facing rivals in Europe, fell 6% on a reported basis in international markets while rising 7.1% in the United States.

AbbVie said the recent approval of Biogen (NASDAQ:BIIB)'s Alzheimer's disease drug had increased interest in treatments that clear brain plaques, a likely contributor to the disease.

The company expects to start testing a drug for Alzheimer's that works on the same mechanism by the end of the year or early next year.

Its shares were 1.7% lower at $116.88 in early trading.

AbbVie expects Botox boom to power annual earnings
 

Related Articles

Calix Up 12% After Craig-Hallum Upgrade
Calix Up 12% After Craig-Hallum Upgrade By Investing.com - Jan 28, 2022

By Sam Boughedda Investing.com — Shares of Calix Inc (NYSE:CALX), the cloud and software services provider, rose 12% Friday after analyst Christian Schwab at Craig-Hallum...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Zara Groß
Zara Groß Jul 30, 2021 14:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nice
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email